Opthea Appoints New CMO and CFO Ahead of Phase 3 Data
Ticker: OPTEY · Form: 6-K · Filed: Oct 8, 2024 · CIK: 1815620
Sentiment: neutral
Topics: executive-appointment, clinical-trials, biotech
TL;DR
Opthea beefs up exec team with new CMO & CFO as it preps for crucial 2025 Phase 3 data.
AI Summary
Opthea Limited announced on October 8, 2024, the appointment of Dr. Moira Miller as Chief Medical Officer and Mr. Matthew Johnson as Chief Financial Officer. These appointments come as the company anticipates topline data readouts from its Phase 3 clinical trials in 2025.
Why It Matters
The appointment of key executives signals Opthea's readiness for significant upcoming milestones, potentially impacting investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — The company is in clinical development with upcoming data readouts, which carry inherent risks of trial success or failure.
Key Players & Entities
- Opthea Limited (company) — Registrant
- Dr. Moira Miller (person) — Appointed Chief Medical Officer
- Mr. Matthew Johnson (person) — Appointed Chief Financial Officer
- 2025 (date) — Anticipated Phase 3 data readouts
FAQ
Who has Opthea Limited appointed to key executive roles?
Opthea Limited has appointed Dr. Moira Miller as Chief Medical Officer and Mr. Matthew Johnson as Chief Financial Officer.
When are Opthea's Phase 3 topline data readouts expected?
Opthea anticipates topline data readouts from its Phase 3 clinical trials in 2025.
What is the primary business of Opthea Limited?
Opthea Limited is in the business of Biological Products (No Diagnostic Substances).
What form is Opthea Limited filing with the SEC?
Opthea Limited is filing a Form 6-K, which is a Report of Foreign Issuer.
Where is Opthea Limited's principal executive office located?
Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.
Filing Stats: 162 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-10-08 06:01:04
Filing Documents
- opt_-_opthea_appoints_cm.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 28KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-113398.txt ( ) — 220KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 10/08/2024